Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Incidence and predictive score for delayed hemolytic transfusion reaction in adult patients with sickle cell disease
source: American Journal of Hematology
year: 2017
authors: Narbey D, Habibi A, Chadebech P, Mekontso-Dessap A, Khellaf M, Lelièvre JD, Godeau B, Michel M, Galactéros F, Djoudi R, Bartolucci P, Pirenne F
summary/abstract:Delayed hemolytic transfusion reaction (DHTR) is a life-threatening complication of transfusion in sickle cell disease (SCD). The frequency of DHTR is underestimated because its symptoms mimic those of vaso-occlusive crisis and antibodies (Abs) are often not detectable. No predictive factors for identifying patients likely to develop DHTR have yet been defined. We conducted a prospective single-center observational study over 30 months in adult sickle cell patients. We included 694 transfusion episodes (TEs) in 311 patients, divided into occasional TEs (OTEs: 360) and chronic transfusion program (CTEs: 334). During follow-up, 15 cases of DHTR were recorded, exclusively after OTEs. DHTR incidence was 4.2% per OTE (95% CI [2.6; 6.9]) and 6.8% per patient during the 30 months of the study (95% CI [4.2; 11.3]). We studied 11 additional DHTR cases, to construct a predictive score for DHTR. The DHTR mortality is high, 3 (11.5%) of the 26 DHTR patients died. The variables retained in the multivariate model were history of DHTR, number of units previously transfused and immunization status before transfusion. The resulting DHTR-predictive score had an area under the ROC curve of 0.850 [95% CI: 0.780-0.930], a negative-predictive value of 98.4% and a positive-predictive value of 50%. We report in our study population, for the first time, the incidence of DHTR, and, its occurrence exclusively in occasionally transfused patients. We also describe a simple score for predicting DHTR in patients undergoing occasional transfusion, to facilitate the management of blood transfusion in SCD patients.
organization: Etablissement Français du Sang, Créteil, France; Institut Mondor de Recherche Biomédicale, lnserm, Créteil, France; Laboratory of Excellence GR-Ex, Paris, France; Hôpital Henri Mondor, Créteil, France; IMRB, Groupe de recherche clinique CARMAS, Créteil, France; Université Paris Est Créteil, Faculté de MédecineDOI: 10.1002/ajh.24908
read more full text
Related Content
-
Mortality Among Women with Sickle Cell Disease Admitted for Delivery, California 2004-2014Maternal mortality results among women w...
-
Red Cell Pain Management Service at St George’s HospitalPeople with sickle cell disease can ofte...
-
Dr. Nina AndersonDr. Nina Anderson, completed her doctora...
-
Acute Care Utilization at End of Life in Sickle Cell Disease: Highlighting the Need for a Palliative ApproachBackground: People with sickle cell dis...
-
When Cracking Down On Opioids Means Tougher Access For Sickle Cell PatientsMany people with sickle cell disease wil...
-
Blood Transfusions: How, Why, and When? (Part 1)https://www.youtube.com/watch?v=KRjjp0Jw...
-
The Life, Death, and Dream of a Research Diversity Crusader“We want to have a nation in which the...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.